The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 18, 2021

Filed:

Dec. 19, 2014
Applicant:

Biomed Valley Discoveries, Inc., Kansas City, MO (US);

Inventors:

Saurabh Saha, Wellesley Hills, MA (US);

Dean Welsch, Parkville, MO (US);

Gary DeCrescenzo, Parkville, MO (US);

Jeffrey James Roix, Boston, MA (US);

Assignee:

BIOMED VALLEY DISCOVERIES, INC., Kansas City, MO (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/4433 (2006.01); A61K 31/444 (2006.01); A61K 45/06 (2006.01); C12Q 1/00 (2006.01); G01N 33/50 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C12Q 1/00 (2013.01); C12Q 1/6886 (2013.01); G01N 33/50 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract

The present invention provides, inter alia, methods, kits, and compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. This method includes administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is an inhibitor of the PI3K/Akt pathway or a pharmaceutically acceptable salt thereof. Also provided are methods of treating or ameliorating the effects of a subject with cancer in which the subject has a somatic KRAS and a somatic PIK3CA mutation or in which the cancer is refractory to a therapy selected from RAF inhibitor therapy, MEK inhibitor therapy, and RAF and MEK inhibitor therapy.


Find Patent Forward Citations

Loading…